Jianda Hu

6.6k total citations
211 papers, 2.5k citations indexed

About

Jianda Hu is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Jianda Hu has authored 211 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Hematology, 69 papers in Molecular Biology and 52 papers in Oncology. Recurrent topics in Jianda Hu's work include Acute Myeloid Leukemia Research (34 papers), Chronic Lymphocytic Leukemia Research (29 papers) and Acute Lymphoblastic Leukemia research (29 papers). Jianda Hu is often cited by papers focused on Acute Myeloid Leukemia Research (34 papers), Chronic Lymphocytic Leukemia Research (29 papers) and Acute Lymphoblastic Leukemia research (29 papers). Jianda Hu collaborates with scholars based in China, United States and Germany. Jianda Hu's co-authors include Yingyu Chen, Xiao‐Jun Huang, Tingbo Liu, Jie Jin, Haijun Chen, Depei Wu, Yu Gao, He Huang, Jianlei Wu and Zhi‐Hong Zheng and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Jianda Hu

188 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jianda Hu China 25 902 705 699 498 417 211 2.5k
Jan Eucker Germany 29 1.0k 1.2× 628 0.9× 760 1.1× 332 0.7× 308 0.7× 85 2.5k
Jianmin Wang China 26 820 0.9× 1.3k 1.9× 700 1.0× 429 0.9× 222 0.5× 141 2.7k
Wenbin Qian China 30 1.4k 1.6× 616 0.9× 997 1.4× 199 0.4× 257 0.6× 170 2.8k
Yi‐Lin Chiu United States 21 1.0k 1.2× 224 0.3× 452 0.6× 268 0.5× 234 0.6× 102 2.6k
Yoko Tabe Japan 31 1.3k 1.5× 936 1.3× 541 0.8× 408 0.8× 141 0.3× 165 3.0k
Takayuki Ikezoe Japan 36 2.6k 2.8× 1.3k 1.8× 1.0k 1.5× 407 0.8× 313 0.8× 205 4.8k
Maria Ilaria Del Principe Italy 30 893 1.0× 1.2k 1.7× 521 0.7× 1.0k 2.1× 646 1.5× 129 2.9k
Sumio Sakamaki Japan 28 1.0k 1.1× 819 1.2× 924 1.3× 336 0.7× 436 1.0× 88 3.3k
Stephen M. Kelsey United Kingdom 27 1.3k 1.4× 759 1.1× 908 1.3× 444 0.9× 243 0.6× 75 2.9k
Emmanuel Gyan France 29 577 0.6× 553 0.8× 1.0k 1.5× 794 1.6× 1.1k 2.7× 164 2.7k

Countries citing papers authored by Jianda Hu

Since Specialization
Citations

This map shows the geographic impact of Jianda Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianda Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianda Hu more than expected).

Fields of papers citing papers by Jianda Hu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jianda Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianda Hu. The network helps show where Jianda Hu may publish in the future.

Co-authorship network of co-authors of Jianda Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Jianda Hu. A scholar is included among the top collaborators of Jianda Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jianda Hu. Jianda Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Li, Jiazheng, Zhengjun Wu, Jingjing Wen, et al.. (2025). UHRF1-mediated epigenetic reprogramming regulates glycolysis to promote progression of B-cell acute lymphoblastic leukemia. Cell Death and Disease. 16(1). 351–351. 2 indexed citations
3.
Wang, Jianxiang, Bin Jiang, Li J, et al.. (2024). Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia. Leukemia. 38(11). 2410–2418. 2 indexed citations
4.
Zhang, Li, Liping Luo, Wenfeng Wang, et al.. (2023). Emodin derivative E35 and its combination with autophagy inhibitor against acute myeloid leukemia cells in vitro and in vivo. Experimental Cell Research. 432(2). 113780–113780. 4 indexed citations
5.
Xu, Jingjing, Quanyi Lu, Yiming Luo, et al.. (2023). When is the best time and grade to start ruxolitinib in corticosteroid‐refractory acute graft‐versus‐host‐disease: A multi‐center research. Clinical Transplantation. 38(1). e15195–e15195. 1 indexed citations
6.
Chen, Yang, Yingping Cao, Peng Yi, et al.. (2022). Differentiation and prognostic stratification of acute myeloid leukemia by serum‐based spectroscopy coupling with metabolic fingerprints. The FASEB Journal. 36(7). e22416–e22416. 12 indexed citations
7.
Chen, Yuwen, Liping Luo, Na Zhang, et al.. (2022). Association of Platelet Desialylation and Circulating Follicular Helper T Cells in Patients With Thrombocytopenia. Frontiers in Immunology. 13. 810620–810620. 16 indexed citations
8.
Wang, Li, Jianda Hu, Wenbin Qian, et al.. (2021). Outcomes in refractory diffuse large B‐cell lymphoma: results from a multicenter real‐world study in China. Cancer Communications. 41(3). 229–239. 17 indexed citations
9.
10.
11.
Wang, Lingyan, et al.. (2021). Characterization of Drug Resistance in Chronic Myeloid Leukemia Cells Based on Laser Tweezers Raman Spectroscopy. Applied Spectroscopy. 75(10). 1296–1304. 3 indexed citations
12.
Chen, Yuwen, Zhengjun Wu, Liping Luo, et al.. (2021). Doxorubicin/Nucleophosmin Binding Protein-Conjugated Nanoparticle Enhances Anti-leukemia Activity in Acute Lymphoblastic Leukemia Cells in vitro and in vivo. Frontiers in Pharmacology. 12. 607755–607755. 9 indexed citations
13.
Wang, Jianxiang, Bin Jiang, Li J, et al.. (2021). Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia. Blood. 138(Supplement 1). 695–695. 5 indexed citations
14.
Song, Yuqin, Keshu Zhou, Dehui Zou, et al.. (2020). Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase. Clinical Cancer Research. 26(16). 4216–4224. 111 indexed citations
15.
Song, Yuqin, Jianqiu Wu, Xinchuan Chen, et al.. (2019). A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma. Clinical Cancer Research. 25(24). 7363–7369. 109 indexed citations
16.
17.
18.
Chen, Yan, Jie Sun, Chao Zhao, et al.. (2016). [Epidemiology of febrile neutropenia in patients with hematological disease-a prospective multicentre survey in China].. PubMed. 37(3). 177–82. 22 indexed citations
19.
Wang, Ling, Jiong Hu, Yuqian Sun, et al.. (2016). Does High-Dose Cytarabine Cause More Fungal Infection in Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy. Medicine. 95(4). e2560–e2560. 10 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jan Eucker Breakdown of academic impact, for papers by Jianmin Wang Breakdown of academic impact, for papers by Wenbin Qian Breakdown of academic impact, for papers by Yi‐Lin Chiu Breakdown of academic impact, for papers by Yoko Tabe Breakdown of academic impact, for papers by Takayuki Ikezoe Breakdown of academic impact, for papers by Maria Ilaria Del Principe Breakdown of academic impact, for papers by Sumio Sakamaki Breakdown of academic impact, for papers by Stephen M. Kelsey Breakdown of academic impact, for papers by Emmanuel Gyan
Rankless by CCL
2026